We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





MeMed Highlights Pioneering Blood Test for Accurately Distinguishing Between Bacterial and Viral Infection

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: MeMed BV blood test accurately distinguishes between bacterial and viral infection (Photo courtesy of MeMed)
Image: MeMed BV blood test accurately distinguishes between bacterial and viral infection (Photo courtesy of MeMed)

MeMed (Haifa, Israel) hosted an integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference (ECCMID) in Lisbon, Portugal, April 23-26, 2022. Clinical key opinion leaders presented clinical use and performance data in scientific sessions, including an integrated symposium, oral abstract presentation and poster abstract on MeMed BV performance validation data.

MeMed BV is a pioneering blood test to help physicians with the seemingly simple clinical dilemma - does a patient have a bacterial or viral infection. The test harnesses the power of the body’s immune system and delivers results in just 15 minutes. MeMed BV measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. MeMed BV is the only test for distinguishing bacterial from viral infections that has been validated in multinational, double-blind and external clinical studies. The clinical studies demonstrating the diagnostic performance of MeMed BV encompassed thousands of patients and are published in high impact medical journals.

Unlike most conventional solutions that seek to detect bacteria or viruses, MeMed BV is an advanced host response test that uses the human immune system as the disease sensor. This approach offers unique advantages far beyond speed and accuracy: (i) It can diagnose cases when the infection site is not readily accessible or is unknown (e.g., pneumonia or fever without source) because immune markers circulate throughout the body; (ii) It can prevent false alarms due to detection of bacteria or viruses that are mere bystanders and are not causing the disease; (iii) It is robust to rapidly evolving pathogens. The MeMed BV test runs on MeMed Key, a cutting edge, compact immunoassay platform that is accurate and easy to use, making it possible to conduct highly sensitive, rapid, multiplexed protein measurements that previously could only be done on expensive central lab equipment.

Related Links:
MeMed 

New
Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
New
COL-R Assay
CHROMagar COL-APSE
New
POC BNP Fluorescence Immunoassay
Quidel Triage BNP Test
New
Multichannel Adjustable-Volume Pipettor
Cole-Parmer Essentials

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.